PROJECT

Projects

Summary of Investment Information

Project Number

38371

Company Name

GLENMARK PHARMACEUTICALS LIMITED

Date SPI Disclosed

Jun 15, 2016

Country

India

Region

South Asia

Projected Board Date

Jun 22, 2016

Environmental Category

B - Limited

Status

Completed

Last Updated Date

Jun 25, 2022

Department

Regional Industry - MAS Asia & Pac

Industry

Health, Education and Life Sciences

Previous Events

Approved : Jun 22, 2016
Signed : Jun 24, 2016
Invested : Jun 28, 2016

Sector

Pharmaceuticals and Medicine

Project Description

Glenmark Pharmaceuticals Limited (“Glenmark” or the “Company”) is an integrated Indian pharmaceuticals company, engaged in the manufacturing of generic pharmaceuticals and discovery and development of new molecules. The proposed project supports the growth of the Company’s pharmaceutical manufacturing facilities in India, create direct and indirect jobs, and increase availability of high quality, affordable drugs. The proposed project will allow the Company to (a) expand its manufacturing capacity (primarily in India) (b) build Research and Development (R&D) capacity for new molecules (including in India) and (c) reduce some debt so that internal accruals can be deployed more for R&D (altogether the “Project”).

Sponsor / Cost / Location

Development Impact

E&S Category Rationale / Risks and Mitigation